Enzerna is developing an RNA editing based technology, called ASRE, for the treatment of rare genetic diseases, namely nucleotide expansion disorders, that cannot be addressed by CRISPR/Cas9 DNA editing technologies. Our approach will deliver adenoviral vectors coding therapeutic ASREs to affected tissues to directly destroy pathogenic RNA molecules that underlie the genetic basis of disease.
Internship Job Description:
The intern will evaluate the DNA vector that will be used to produce adenoviruses for our first gene therapy studies in animal models of the nucleotide expansion disorder, myotonic dystrophy. The intern will learn techniques such cell culture, transfection, protein and RNA isolation, Western blotting and quantitative PCR to validate expression of the therapeutic gene from the DNA vector.
This internship requires a commitment of 30 hours per week over 12 weeks, and is available starting in May.
This internship is supported in part by a grant from the North Carolina Biotechnology Center through the Industrial Internship Program.
No prior research experience required.
Classwork: AP biology or entry level college Biology
Type and Timing of Internship:
Apply on website